Search clinical trials for: SCB-2019

Total 3253 results

MedImmune LLC
AstraZeneca

Completed

Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age (FluMist)

Healthy | Influenza

United States
Chang Gung Memorial Hospital

Completed

Nonoperative Management Protocol in Patients With Blunt Splenic Injuries

Blunt Injuries
Duke University
Centers for Disease Control and Prevention; Children's Hospital Medical Center...

Completed

Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women (Tdap/IIV)

Pregnancy

United States
Clover Biopharmaceuticals AUS Pty Ltd

Completed

Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19.

COVID-19

Australia
Clover Biopharmaceuticals AUS Pty Ltd

Completed

SCB-2019 as COVID-19 Vaccine

COVID-19

Australia
Clover Biopharmaceuticals AUS Pty Ltd

Withdrawn

Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age

COVID-19

Colombia
Clover Biopharmaceuticals AUS Pty Ltd
International Vaccine Institute; Coalition for Epidemic Preparedness Innovations

Completed

A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (SCB-2019)

COVID-19

Colombia, Belgium, Brazil, Philippines, South Africa
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations (GRC90)

Influenza

United States
University of Sao Paulo General Hospital

Completed

Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases

Sjogren's Syndrome | Systemic Lupus

Brazil
D'Or Institute for Research and Education
Bill and Melinda Gates Foundation; University of Oxford

Not yet recruiting

An Observer-blind, Cohort Randomized, Exploratory Phase 3 Study to Evaluate the Safety and Immunogenicity of Recombinant Covid-19 Vaccine, mRNA Covid-19 Vaccine and Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine as 4th Dose in Individuals Primed/ Boosted With Various Regimens

COVID-19

Brazil
D'Or Institute for Research and Education
Bill and Melinda Gates Foundation

Active, not recruiting

Assessment of Immunogenicity, Safety and Reactogenicity of a Booster Dose of Various COVID-19 Vaccine Platforms in Individuals Primed With Several Regimes.

COVID-19

Brazil
Anderson Clinical Research
Ligand Pharmaceuticals

Completed

A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma

HIV Infections | Sarcoma, Kaposi
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.

Influenza

United States
Addpharma Inc.

Not yet recruiting

Phase III Study to Evaluate the Efficacy and Safety of AD-209

Hypertension,Essential

Korea, Republic of
Addpharma Inc.

Completed

Evaluating the Pharmacokinetic Interaction Between AD-2011 and AD-2012

Hypertension | Hyperlipidemias

Korea, Republic of
Zhejiang Clover Biopharmaceuticals, Inc.

Active, not recruiting

Immunogenicity and Safety Study of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adultsin China

COVID-19

China
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults

Influenza

United States
Clover Biopharmaceuticals AUS Pty Ltd

Recruiting

First-in-human Safety and Immunogenicity Study of SCB-1019 in Healthy Adults

Respiratory Syncytial Virus Infection

Australia
Tianjin Chest Hospital

Recruiting

Optimal Evaluation to Reduce Imaging Testing (OPERATE)

Chronic Coronary Syndrome

China
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India

Influenza

India
Inter-American Development Bank

Completed

Randomized Trial of the Effects of Musical Training on Child Development in the Venezuela Orchestra Program (El Sistema)

Child Development
University of Southern Denmark
University of Copenhagen; University of Aarhus; The Danish Institute for Quality...

Unknown

The Effectiveness of a Nationwide Mandatory Accreditation in General Practice in Denmark (ACIAP)

Quality Control
Emory University

Completed

The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination (FLU1)

Influenza

United States
Chimerix

Terminated

A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease (SUSTAIN)

Cytomegalovirus Disease

United States
David Scheifele
Canadian Institutes of Health Research (CIHR)

Completed

Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults Receiving Seasonal Influenza Vaccine

Influenza | H1N1 2009 Influenza

Canada
Seqirus

Completed

A Study to Assess the Immunogenicity and Safety of CSL's 2009 / 2010 Formulation of Enzira® Vaccine in Healthy Volunteers

Influenza

United Kingdom
GlaxoSmithKline

Completed

A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2012/2013 in People Aged 18 Years and Above

Influenza

Germany
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV Immunization (SLVP023)

Influenza
Adimmune Corporation

Completed

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Healthy Subjects Aged Over 6 Months Old to 18 Years Old

Influenza
Adimmune Corporation

Completed

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Non-Elderly Adult and Elderly Subjects

Influenza
Children's Hospital Medical Center, Cincinnati

Completed

Flu Vaccine Study in Neuromuscular Patients 2011

Duchenne Muscular Dystrophy | Spinal Muscular Atrophy | Congenital Muscular Dystrophy
Sinovac Biotech Co., Ltd

Completed

The Immunogenicity and Safety of 2012-2013 Trivalent Seasonal Influenza Vaccine

Influenza

China
Medical University of Lodz
GlaxoSmithKline

Not yet recruiting

Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma

Asthma; Eosinophilic

Poland
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix®/Influsplit SSW® (2013/2014 Season), in Adults 18 Years of Age and Older

Influenza

Germany
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine, Fluarix/Influsplit Tetra® (2013/2014 Season), in Adults 18 Years of Age and Older

Influenza

Germany
GlaxoSmithKline

Terminated

Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM

Influenza

Germany
Crucell Holland BV

Completed

Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains

Influenza

Switzerland
Mount Sinai Hospital, Canada
GlaxoSmithKline

Completed

Does Seasonal Influenza Vaccination Affect the Incidence of pH1N1 Influenza?

Influenza

Canada
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults

Influenza

United States
Clover Biopharmaceuticals AUS Pty Ltd

Completed

Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults

COVID-19

Philippines
Seqirus

Completed

A Clinical Trial of CSL's 2010/2011 Formulation of Enzira® in a Healthy Adult Population

Influenza

United Kingdom
Novartis Vaccines

Completed

Safety and Immunogenicity of One Dose of Inactivated Trivalent Flu Vaccine Administered to Non-elderly Adult and Elderly Subjects

Seasonal Influenza

Italy
University Hospital, Ghent
CEVAC Core Lab, University Ghent; Max Planck Institute for Infection Biology... and other collaborators

Completed

Study of Biomarkers of Immune Activation Associated With Symptoms and Immune Responses After Influenza Vaccination in Adults

Prevention of Influenza

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects

Seasonal Influenza

Germany
Center for Human Reproduction
Foundation for Human Reproduction

Enrolling by invitation

Effect of Influenza Vaccination on IVF Outcomes - IVF (IVF-FluVac)

Infertility

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years

Influenza

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects (FBP00004)

Healthy Volunteers | Influenza Immunisation

United States
Center for Human Reproduction
Foundation for Human Reproduction

Unknown

Effect of Influenza Vaccination on Donor Egg Recipient Outcomes (DE-FluVac)

Infertility | Recurrent Miscarriage

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults

Influenza

United States

3

Subscribe